An economic analysis of more than a decade of federal survey data found that adults with diabetes who started GLP-1 medications showed no measurable change in mental health, self-rated health, employment, or marital status compared with their own earlier circumstances.
The finding comes from a National Bureau of Economic Research working paper by University of Chicago Harris School of Public Policy economist Robert Kaestner and coauthor Cuiping Schiman. The paper was issued in May, was publicized by the University of Chicago in late July, and has circulated more widely in recent weeks.
